Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENVEC files S-1 -- Ignore unavailable to you. Want to Upgrade?

To: pgo-neil who wrote (18)	7/27/2009 4:12:58 PM
From: Gary Mohilner	Respond to of 30

I believe the beauty of TNFerade is its ability to work with nearly all other therapies and the fact that it may applied to far more than the few cancers it's currently in trials with. We know it works with Pancreatic, Esophageal, and Head and Neck Cancers, but what if it works with Lung, or Breast, or Colon, etc. etc. Once we have a partner I would expect that many new trials will will be established for other cancer, but not immediately, as it takes time to develop the new protocols, but with funds no longer a problem, it should happen fully funded by our partner. While we cannot know the earning capacity of TNFerade without further trials, it's potential is huge as it may be determined to work with many types of solid tumors. Gary